FibroGen (NASDAQ: FGEN) and Compugen (NASDAQ:CGEN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Valuation and Earnings

This table compares FibroGen and Compugen’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
FibroGen $179.58 million 21.12 -$61.68 million ($2.04) -22.62
Compugen $710,000.00 187.24 -$31.50 million ($0.71) -3.66

Compugen has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares FibroGen and Compugen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FibroGen -120.00% -47.36% -23.51%
Compugen N/A -70.91% -60.92%

Volatility & Risk

FibroGen has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Compugen has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for FibroGen and Compugen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FibroGen 0 2 5 1 2.88
Compugen 0 0 1 0 3.00

FibroGen currently has a consensus target price of $65.67, suggesting a potential upside of 42.29%. Compugen has a consensus target price of $14.00, suggesting a potential upside of 438.46%. Given Compugen’s stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than FibroGen.

Insider and Institutional Ownership

57.2% of FibroGen shares are owned by institutional investors. Comparatively, 17.4% of Compugen shares are owned by institutional investors. 13.6% of FibroGen shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

FibroGen beats Compugen on 8 of the 14 factors compared between the two stocks.

FibroGen Company Profile

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Compugen Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.